I don't think so, remember the MAP scores and efficacy of nearly 70% survival vs 20 % outweighs the potential negatives here.
Figures from the Kasikis et al 2021 paper are based on "25of the 54 pediatric study patients with serum samples taken at thebeginning of treatment being compared to 27 closely matched pediatricpatients with SR acute GVHD who participated in a prospective GVHDnatural history study"
The survival differentials that turned up in Kasikis suggest something better about the 25 but as all the 25 came from just 3 donor cell banks how can you be sure that what those three donor's cells were providing as the potency factor that made their recipients chances better was TNFR1 expression rather than say the cells handling of interferon gamma?
If it was interferon gamma handling not TNF alpha handling that made the cells potent and you don't know that then how do you know you won't miss the actually potency factor in the next donor cell bank you release test by using TNFR1 expression rather than another potency assay?
MSB Price at posting:
91.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)